Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felodipine dose-tolerability trial in early-stage Huntington's disease
ISRCTN56240656Phase 2Completed
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of felodipine in Huntington disease (HD) (3 cohorts), sponsored by Cambridge Clinical Trials Unit. Primary endpoint: Number of adverse events attributable to felodipine. Started Aug 2022; status: completed.
02
Drugs
felodipine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on ISRCTN56240656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN56240656.